
News|Articles|February 3, 2025
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
Author(s)PurpleLab
A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Trending on Applied Clinical Trials Online
1
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
2
ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma
3
Unlocking Unstructured Health Data: Scaling eSource-Enabled Clinical Trials
4
Designing Engagement Solutions That Don’t Add to Site Workload
5